BIO-RAD LABORATORIES INC
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders' Equity
| Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
|---|---|---|---|---|---|---|
| Balance at December 31, 2023 | $3 | $449,075 | $(632,536) | $9,260,629 | $(336,038) | $8,741,133 |
| Net income | — | — | — | 383,916 | — | 383,916 |
| Other comprehensive loss, net of tax | — | — | — | — | (89,933) | (89,933) |
| Share-based compensation expense | — | 15,262 | — | — | — | 15,262 |
| Purchase of treasury stock | — | — | (4,702) | — | — | (4,702) |
| Reissuance of treasury stock | — | (1,710) | 7,215 | — | — | 5,505 |
| Excise tax on stock repurchase | — | — | (47) | — | — | (47) |
| Balance at March 31, 2024 | $3 | $462,627 | $(630,070) | $9,644,545 | $(425,971) | $9,051,134 |
| Net loss | — | — | — | (2,165,486) | — | (2,165,486) |
| Other comprehensive loss, net of tax | — | — | — | — | (25,391) | (25,391) |
| Share-based compensation expense | — | 14,999 | — | — | — | 14,999 |
| Purchase of treasury stock | — | — | (100,000) | — | — | (100,000) |
| Reissuance of treasury stock | — | (2,745) | 7,428 | — | — | 4,683 |
| Shares withheld related to net share settlement of equity awards | — | (152) | — | — | — | (152) |
| Excise tax on stock repurchase | — | — | (1,000) | — | — | $(1,000) |
| Balance at June 30, 2024 | $3 | $474,729 | $(723,642) | $7,479,059 | $(451,362) | $6,778,787 |
| Net income | — | — | — | 653,172 | — | 653,172 |
| Other comprehensive income, net of tax | — | — | — | — | 136,088 | 136,088 |
| Share-based compensation expense | — | 15,675 | — | — | — | 15,675 |
| Purchase of treasury stock | — | — | (96,868) | — | — | (96,868) |
| Reissuance of treasury stock | — | (38,947) | 44,049 | — | — | 5,102 |
| Shares withheld related to net share settlement of equity awards | — | (3,128) | — | — | — | (3,128) |
| Excise tax on stock repurchase | — | — | (969) | — | — | $(969) |
| Balance at September 30, 2024 | $3 | $448,329 | $(777,430) | $8,132,231 | $(315,274) | $7,487,859 |
Condensed Consolidated Statements of Changes in Stockholders' Equity
| Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
|---|---|---|---|---|---|---|
| Balance at December 31, 2022 | $3 | $447,454 | $(263,586) | $9,898,203 | $(466,822) | $9,615,252 |
| Net income | — | — | — | 68,962 | — | 68,962 |
| Other comprehensive income, net of tax | — | — | — | — | 58,470 | 58,470 |
| Share-based compensation expense | — | 16,608 | — | — | — | 16,608 |
| Reissuance of treasury stock | — | (660) | 5,290 | (206) | — | 4,424 |
| Balance at March 31, 2023 | $3 | $463,402 | $(258,296) | $9,966,959 | $(408,352) | $9,763,716 |
| Net loss | — | — | — | (1,162,251) | — | (1,162,251) |
| Other comprehensive income, net of tax | — | — | — | — | 35,490 | 35,490 |
| Share-based compensation expense | — | 12,559 | — | — | — | 12,559 |
| Purchase of treasury stock | — | — | (207,407) | — | — | (207,407) |
| Reissuance of treasury stock | — | (2,089) | 6,919 | (44) | — | 4,786 |
| Balance at June 30, 2023 | $3 | $473,872 | $(458,784) | $8,804,664 | $(372,862) | $8,446,893 |
| Net income | — | — | — | 106,257 | — | 106,257 |
| Other comprehensive loss, net of tax | — | — | — | — | (124,699) | (124,699) |
| Issuance of common stock, net of shares withheld | — | (5,111) | — | — | — | (5,111) |
| Share-based compensation expense | — | 15,952 | — | — | — | 15,952 |
| Purchase of treasury stock | — | — | (23,608) | — | — | (23,608) |
| Reissuance of treasury stock | — | (45,258) | 45,772 | — | — | 514 |
| Balance at September 30, 2023 | $3 | $439,455 | $(436,620) | $8,910,921 | $(497,561) | $8,416,198 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.